- Home
- PINE vs LUNG Comparison
PINE vs LUNG Comparison
Compare PINE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- LUNG
- Stock Information
- Founded
- PINE 2019
- LUNG 1995
- Country
- PINE United States
- LUNG United States
- Employees
- PINE N/A
- LUNG N/A
- Industry
- PINE Real Estate Investment Trusts
- LUNG Industrial Specialties
- Sector
- PINE Real Estate
- LUNG Health Care
- Exchange
- PINE Nasdaq
- LUNG Nasdaq
- Market Cap
- PINE 220.4M
- LUNG 124.0M
- IPO Year
- PINE 2019
- LUNG 2020
- Fundamental
- Price
- PINE $14.71
- LUNG $2.58
- Analyst Decision
- PINE Strong Buy
- LUNG Buy
- Analyst Count
- PINE 8
- LUNG 6
- Target Price
- PINE $19.00
- LUNG $11.53
- AVG Volume (30 Days)
- PINE 79.2K
- LUNG 360.8K
- Earning Date
- PINE 07-24-2025
- LUNG 07-30-2025
- Dividend Yield
- PINE 7.71%
- LUNG N/A
- EPS Growth
- PINE N/A
- LUNG N/A
- EPS
- PINE 0.07
- LUNG N/A
- Revenue
- PINE $53,967,000.00
- LUNG $87,473,000.00
- Revenue This Year
- PINE $8.54
- LUNG $18.02
- Revenue Next Year
- PINE $3.03
- LUNG $18.17
- P/E Ratio
- PINE $198.78
- LUNG N/A
- Revenue Growth
- PINE 14.94
- LUNG 19.84
- 52 Week Low
- PINE $14.51
- LUNG $2.50
- 52 Week High
- PINE $19.42
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- PINE 40.21
- LUNG 35.17
- Support Level
- PINE $14.93
- LUNG $2.50
- Resistance Level
- PINE $15.32
- LUNG $2.80
- Average True Range (ATR)
- PINE 0.27
- LUNG 0.18
- MACD
- PINE -0.03
- LUNG 0.01
- Stochastic Oscillator
- PINE 8.82
- LUNG 13.82
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.